Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2000
12/19/2000US6162829 (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
12/19/2000US6162827 Treatment of negative and cognitive symptoms of schizophrenia with D-serine
12/19/2000US6162819 Pyrazole derivatives, their preparation and their use in pharmaceuticals
12/19/2000US6162818 Respiratory system disorders; crohn's disorder; cardiovascular disorders
12/19/2000US6162817 Stroke therapy; brain disorders; crohn's disease
12/19/2000US6162813 Antagonists of gonadotropin releasing hormone
12/19/2000US6162790 Oligopeptides
12/19/2000US6162600 Indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
12/19/2000US6162431 Serine/threonine protein kinase
12/19/2000CA2234826C Fluoxetine enteric pellets
12/14/2000WO2000075365A2 Compounds and methods to enhance raav transduction
12/14/2000WO2000075348A1 Recombinant anti-cd40 antibody and uses thereof
12/14/2000WO2000075334A1 Apoptosis inhibition by adenovirus e3/6.7k
12/14/2000WO2000075328A1 Human sel-10 polypeptides and polynucleotides that encode them
12/14/2000WO2000075318A1 Phospholipid transfer protein
12/14/2000WO2000075309A1 Spliceosome protein and its use
12/14/2000WO2000075290A1 Method for multiplying stem cells
12/14/2000WO2000075279A2 Nucleotide sequences for gene regulation and methods of use thereof
12/14/2000WO2000075186A1 Neuromedin b and somatostatin receptor agonists
12/14/2000WO2000075176A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000WO2000075173A2 Peptide fragments of colostrinin
12/14/2000WO2000075163A1 Angiogenic proteins and uses thereof
12/14/2000WO2000075144A2 Peroxynitrite decomposition catalysts and methods of use thereof
12/14/2000WO2000075139A2 Benzothiazinone and benzoxazinone compounds
12/14/2000WO2000075126A1 Mycolactone and related compounds, compositions and methods of use
12/14/2000WO2000075123A1 Substituted 5-oxo-5,6,7,8-tetrahydro-4h-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of ampa
12/14/2000WO2000075117A1 Compositions and methods for inhibiting cell death
12/14/2000WO2000075116A2 Tricyclic analgesics
12/14/2000WO2000075114A1 Beta2-adrenoceptor agonists
12/14/2000WO2000075110A1 Pharmaceutical compositions and methods for use
12/14/2000WO2000075109A1 Ethanesulfonyl-piperidine derivatives
12/14/2000WO2000075107A2 Bradykinin receptor antagonists
12/14/2000WO2000075101A1 Excitatory amino acid receptor modulators
12/14/2000WO2000074784A1 Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
12/14/2000WO2000074742A1 Devices and compounds for treating arterial restenosis
12/14/2000WO2000074724A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells
12/14/2000WO2000074718A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000WO2000074717A1 NOVEL Ig FRACTIONS HAVING AN IMMUNOMODULATORY ACTIVITY
12/14/2000WO2000074712A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
12/14/2000WO2000074710A2 Methods for treating diabetes
12/14/2000WO2000074706A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000WO2000074703A2 Therapeutic agent comprising a botulinum neurotoxin
12/14/2000WO2000074695A2 Tanacetum parthenium extract
12/14/2000WO2000074680A1 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
12/14/2000WO2000074676A1 Use of riluzole for the treatment of multiple sclerosis
12/14/2000WO2000074666A2 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
12/14/2000WO2000074664A2 Novel iron chelators and pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders
12/14/2000WO2000074659A1 Morphine sulphate microgranules, method for preparing same and compositions containing same
12/14/2000WO2000074652A1 Pharmaceutical composition for nasally administering water-soluble active substances
12/14/2000WO2000074651A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
12/14/2000WO2000063208B1 Substituted imidazoles, their preparation and use
12/14/2000WO2000050562A3 Dna encoding snorf25 receptor
12/14/2000WO2000049135A3 Substrate for cell growth
12/14/2000WO2000047716A3 Fibres for culturing eukaryotic cells
12/14/2000WO2000047284A3 Novel use of orexin receptor antagonists
12/14/2000WO2000045770A3 Compressed lecithin preparations
12/14/2000WO2000044763A3 Compositions for treating inflammatory response
12/14/2000WO2000044408A3 Method of treating demyelinating inflammatory disease using ccr1 antagonists
12/14/2000WO2000006187A9 Modulation of apoptosis
12/14/2000CA2751187A1 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid and derivatives thereof for treatment of hyperuricemia
12/14/2000CA2390090A1 Peptides
12/14/2000CA2376729A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000CA2376506A1 Neuromedin b and somatostatin receptor agonists
12/14/2000CA2376400A1 Compounds and methods to enhance raav transduction
12/14/2000CA2376335A1 Novel ig fractions having an immunomodulatory activity
12/14/2000CA2376314A1 Apoptosis inhibition by adenovirus e3/6.7k
12/14/2000CA2376215A1 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
12/14/2000CA2376210A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000CA2376076A1 Tricyclic analgesics
12/14/2000CA2376061A1 Pharmaceutical compositions and methods for use
12/14/2000CA2376055A1 Spliceosomal protein and its use
12/14/2000CA2376048A1 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
12/14/2000CA2376018A1 Angiogenic proteins and uses thereof
12/14/2000CA2376010A1 Mycolactone and related compounds, compositions and methods of use
12/14/2000CA2375912A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000CA2375874A1 Use of riluzole for the treatment of multiple sclerosis
12/14/2000CA2375843A1 Compositions and methods for inhibiting cell death
12/14/2000CA2375734A1 Benzothiazinone and benzoxazinone compounds
12/14/2000CA2375485A1 Method for multiplying stem cells
12/14/2000CA2374558A1 Phospholipid transfer protein
12/14/2000CA2373336A1 Peroxynitrite decomposition catalysts and methods of use thereof
12/13/2000EP1059088A1 New Ig-fractions with immunomodulation activity
12/13/2000EP1058730A1 Human synapse related glycoproteins (hsrp)
12/13/2000EP1058726A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines
12/13/2000EP1058684A1 Glycine transport inhibitors
12/13/2000EP1058680A1 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
12/13/2000EP1058551A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders and autism
12/13/2000EP1058550A1 Substituted semicarbazides and the use thereof
12/13/2000EP1058544A1 Inhibition of tnf activity
12/13/2000EP0724583B1 Pyridazino quinoline compounds
12/13/2000CN1276790A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them
12/13/2000CN1276784A Cyclic amino acids and derivs. thereof useful as pharmaceutical agents
12/13/2000CN1276782A 2-aminotetralines, process for their preparation, and pharmaceutical compositions, for prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
12/13/2000CN1276722A N, N-bis(phenylcarbamoylmethyl) dimethylammonium chloride and derivs in treatment of pain
12/13/2000CN1276704A Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing abuse of alcohol in healthy subjects
12/13/2000CN1276236A Exterior-applied medical liquor
12/13/2000CN1276228A Chinese medicine for dropping drug and its preparing process
12/13/2000CN1276211A Use of non-peptides NK3-antagonist
12/13/2000CN1276209A Application of tripterygium plant extract in preventing and curing diseases in nervous system
12/13/2000CN1059443C Tetracylic 1,4-oxazine compound, its preparing method and medicinal composition contg. same
1 ... 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 ... 1833